Selection and Counterselection of the rtI233V Adefovir Resistance Mutation during Antiviral Therapy

被引：22

作者：

Schildgen, Oliver ^{[2
]}

Olotu, Cynthia ^{[1
]}

Funk, Anneke ^{[1
]}

Zoellner, Bernhard ^{[3
]}

Helm, Martin

Rockstroh, Juergen Kurt ^{[4
]}

Sirma, Hueseyin ^{[1
]}

机构：

[1] Heinrich Pette Inst, Hamburg, Germany

[2] Kliniken Stadt Koln, Inst Pathol, Cologne, Germany

[3] Univ Hamburg, Inst Med Microbiol, Hamburg, Germany

[4] Univ Bonn, Dept Med 1, D-5300 Bonn, Germany

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2010年 / 48卷 / 02期

关键词：

HEPATITIS-B-VIRUS; HBV POLYMERASE; VIRAL LOAD; DIPIVOXIL; LAMIVUDINE; INFECTION;

D O I：

10.1128/JCM.01073-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir (ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation. Here, we describe two further patients with chronic HBV infection who were found to develop the rtI233V mutation after initiation of ADF therapy. These patients represent the first cases known so far in which the rtI233V ADF resistance mutation evolved under persistent HBV replication during HBV therapy with ADF. Interestingly, one of the previously described patients, who was initially successfully switched from ADF to tenofovir (TDF) and became virologically suppressed subsequently, experienced a moderate but remarkable rebound of HBV viremia after switching from TDF to entecavir, due to the emergence of renal toxicity. Thus, we provide evidence for the selection and counterselection of the rtI233V ADF resistance mutation during antiviral therapy.

引用

页码：631 / 634

页数：4

共 20 条

[1] Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].